ImmuPharma plc
Status: Publicly traded
Direct answer
ImmuPharma plc is publicly traded on LSE under the ticker IMM.L.
ImmuPharma plc is a biopharmaceutical company dedicated to the discovery and development of peptide-based therapeutic solutions. The firm's innovative treatments address a range of medical fields, including autoimmune and inflammatory disorders, as well as anti-infective applications. Leading its pipeline is Lupuzor, an autophagy immunomodulator, which is presently undergoing Phase III clinical trials for the...
Can you invest in ImmuPharma plc?
Yes. ImmuPharma plc trades publicly on LSE as IMM.L.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for ImmuPharma plc
Detailed equity research is provided by MarketSnap.